StemCyte Renews Contract with California's Umbilical Cord Blood Program

BALDWIN PARK, Calif., May 23, 2024 — StemCyte, a prominent player in cord blood-based regenerative medicine in Southern California, is pleased to announce the extension of its partnership with the California State Umbilical Cord Blood Collection Program (CA-UCBCP). This collaboration with UC Davis Health has significantly boosted StemCyte's cord blood collection initiatives.

StemCyte places a high value on ethnic diversity in cord blood banking. Since 2013, the company has banked numerous cord blood units from Latino, Asian, and African American communities, serving as the primary supplier of transplant units through the CA-UCBCP. The renewed contract brings increased funding to diversify the NMDP National Registry further, ensuring that individuals from all racial and ethnic backgrounds have access to genetically compatible cord blood units. Additionally, StemCyte and UC Davis Health are set to introduce new hospital collection sites in Palm Springs and Sacramento later this year.

Dr. Tong-Young Lee, CEO of StemCyte, expressed his excitement about the renewed partnership: "We are thrilled to continue our collaboration with the CA-UCBCP, enabling us to educate and empower expectant mothers and their families to contribute to life-saving treatments through cord blood donation. Our renewed alliance with the CA-UCBCP underscores our unyielding commitment to enhancing racial diversity in cord blood donations and supporting families facing serious health challenges."

Since the first umbilical cord blood transplant in 1988, approximately 60,000 patients worldwide have benefited from these procedures for various hematopoietic, immune, and metabolic disorders. StemCyte has been instrumental in this field, supplying over 2,300 cord blood units for transplants and aiding 1 in 26 patients globally. The company’s adherence to international quality standards has earned the trust of more than 350 transplant centers worldwide, including the top eight transplant centers in the United States.

In its quest for innovation, StemCyte submitted a Biologics License Application (BLA) for its HPC, Cord Blood product RegeneCyte® to the FDA in January 2022. This product is designed to provide hematopoietic and immunologic reconstitution in patients with hematopoietic system disorders through unrelated donor transplantation procedures.

As a pioneer in regenerative cell therapy, StemCyte offers both public and private umbilical cord blood banking services and is actively developing new treatments. The company is sponsoring several ongoing clinical trials, including Phase II trials using cord blood for post-COVID syndrome and cord blood-derived mononuclear cells for spinal cord injury. Additionally, a Phase II trial for acute ischemic stroke is planned for 2024. Compassionate use treatments with HPC, Cord Blood, and umbilical cord mesenchymal stem cells (MSC) have shown promising results in treating conditions such as cerebral palsy and hypoxic ischemic encephalopathy.

As StemCyte continues to explore innovative regenerative cell therapy avenues for product development, it remains devoted to advancing medical science and improving patient outcomes. The company envisions a future where the potential of cord blood therapies is fully realized, offering new hope and healing to patients worldwide.

StemCyte's global headquarters is located in Baldwin Park, California, with additional operations in Taiwan and India. The company operates a unique dual public and private bank, accredited by both AABB and FACT. StemCyte is committed to enhancing the quality of life for more individuals globally through the innovative use of cord blood and related stem cell therapies.